Logo of global biopharmaceutical company Bristol-Myers Squibb is pictured on the blouse of an employee in Le Passage, near Agen, France March 29, 2018. REUTERS/Regis Duvignau
(Reuters) – Bristol-Myers Squibb Co (BMY.N) received an offer from Japanese healthcare firm Taisho Pharmaceutical Holdings Co Ltd (4581.T) to buy the company’s French over-the-counter drugs business UPSA for $1.6 billion, the companies said on Wednesday.
The offer by Taisho is structured in the form of a “put option” agreement, the companies said.
Bristol-Myers said it estimates the potential deal would be approximately $0.04 dilutive to 2019 earnings.
Reporting by Rama Venkat in Bengaluru; Editing by Sunil Nair
Our Standards:The Thomson Reuters Trust Principles.
This article was originally published by Reuters.com. Read the original article here.
